Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.

Chambers, James D; Enright, Daniel E; Panzer, Ari D; Cohen, Josh T; Ollendorf, Daniel A; Neumann, Peter J

Chambers, James D; Enright, Daniel E; Panzer, Ari D; Cohen, Josh T; Ollendorf, Daniel A; Neumann, Peter J.

Afiliação

Chambers JD; The Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Enright DE; The Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Panzer AD; The Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Cohen JT; The Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Ollendorf DA; The Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Neumann PJ; The Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.

J Manag Care Spec Pharm ; 29(3): 257-264, 2023 Mar.

Article em En | MEDLINE | ID: mdl-36840954

Assuntos

Análise Custo-Benefício; Cobertura do Seguro; Seguro Saúde; Humanos; Estados Unidos; Seguro Saúde/economia; Cobertura do Seguro/economia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Análise Custo-Benefício / Cobertura do Seguro / Seguro Saúde Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google